Evaluation of remineralizing efficiency of two calcium-based non-fluoridated remineralizing agents for the prevention of white spot lesions (WSL): A comparative FESEM & EDS in-vitro study
Abstract
This research work was designed to appraise and equate the remineralizing efficiency of two calcium-based phosphate delivery agents, Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP) and Calcium Sucrose Phosphate (CaSP) for preventing the development of White Spot Lesions (WSL) around the orthodontic brackets. Forty orthodontically removed premolar teeth were randomly allocated to Group 1(n=20) - (CPP-ACP) and Group 2(n=20) - (CaSP). All the specimens were subjected to FESEM and EDS analysis before the initial demineralization phase and after 14 days of the pH cycling phase, to observe and record changes in surface topography and mineral content (Ca/P ratio % wt.). Statistical data for the Intragroup comparison were analyzed by using Paired sample t-test, whereas for the Intergroup comparison, an Unpaired t-test was performed. Furthermore, the One-way ANOVA test was applied for comparing Intragroup data and the Post-hoc Tukey test was applied to compare Intergroup data. Group 1 samples showed an 11.3%increase in remineralization and Group 2 samples showed a 21.3%increase in remineralization, indicating a statistically significant (p < 0.05) 11% of greater remineralizing efficiency of CaSP. The use of Calcium Sucrose Phosphate (CaSP) tooth cream around the orthodontic brackets seems to produce significantly better remineralization effects.
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.